New Alzheimer's drug QLH2405 enters first human safety tests
NCT ID NCT07489599
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests a single injection of QLH2405 in 68 healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The main goal is to check safety and how the body processes the drug. It is too early to know if QLH2405 will help treat Alzheimer's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLH2405 injection
- What this could lead to
- If safe and effective, QLH2405 could point toward a new treatment to slow or manage early Alzheimer's disease.
- What could go wrong
- This is a very early Phase 1 trial with only 68 participants, focused on safety, not proof of benefit. The drug may fail to show any effect or have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily probiotic help protect aging brains?
- AI chat could be a secret weapon against dementia in lonely seniors
- Could family and community support help slow cognitive decline?
- Zapping the brain to boost memory and mood in Alzheimer's
- Sound waves aim to boost brain function in memory loss
- Tailored sound waves may sharpen the mind